-kit encodes the transmembrane receptor tyrosine kinase (Kit) for the recently described ligand stem cell factor (SCF). We have developed an enzyme-linked immunosorbent assay for measuring soluble human Kit and we have used the assay to show high levels of soluble Kit in human serum. The distribution of soluble Kit levels was investigated among 112 normal human serum donors. The mean serum level (?SDI was found to be 324 ? 105 ngImL with the values falling between 163 nglmL and 788 ngImL. No correlation between soluble K t levels and the sexes or ages of the donors was found. Partial purification using immunoaffinity chromatography allowed us to characterize the soluble Kit from pooled human serum. Antibodies generated to a 497-amino acid recombinant human soluble Kit corresponding to the N-termina1 extracellular domain of the receptor recognized the HE ONCOGENE v-kit was described as part of the genome of the Hardy-Zuckerman 4 feline sarcoma virus (HZ4-FeSV).' The corresponding cellular proto-oncogene c-kit is located on human chromosome 4 and on mouse chromosome 5, and encodes a transmembrane receptor tyrosine kinase (Kit) that is structurally related to the receptor for macrophage colony-stimulating factor (M-CSF) and the receptor for platelet-derived growth factor (PDGF).' In this group of receptor tyrosine kinases (type 111; split kinase family), the cytoplasmic catalytic domains are interrupted by long hydrophilic insertion sequences and the extracellular ligand-binding portions consist of five IgG-like domains.? FLT3/FLK2 receptor is a recent addition to this family!.' Avian: m~r i n e ,~ and human2 Kit cDNAs have been cloned and structurally analyzed. The human cDNA encodes a short signal sequence (amino acids 1 through 23 in the numbering of Yarden et al') followed by extracellular domain (amino acids 24 through 520, including 10 potential sites of Nlinked glycosylation), transmembrane domain (amino acids 521 through 543), and intracellular domain (amino acids 544 through 976). The polypeptide without the signal sequence has a calculated molecular weight of 109,740 whereas the major expression product is a glycoprotein of about 145,000 daltons.' The human c-kit gene includes 21 cDNAs corresponding to two distinct isoforms of Kit have been described for both murine" and human.9 The two isoforms differ by the presence (Kit A) or absence (Kit) of four amino acids (Gly-Asn-Asn-Lys) at codons 5 10 through 513 (numbered according to the human sequence of Yarden et a12) in the extracellular portion just before the transmembrane 
serum-derived soluble Kit by immunoblotting. We found that the serum-derived soluble Kit is glycosylated, with mostly N-linked but also 0-linked carbohydrate, and with terminal sialic acid residues. When compared with the recombinant human soluble Kit, the serum-derived material was similar both in size and glycosylation pattern. CNBr cleavage of the isolated serum-derived material followed by amino terminal sequencing confirmed the presence of five peptides expected for the extracellular portion of the Kit molecule. The immunoaffinity purified serum-derived soluble Kit domain.'." These isoforms are generated by alternative splicing events at the 3' end of exon 9.9 In 1988 it was reported that the c-kit gene and the white spotting (W) locus in the mouse are a l l e l i~. "~~~ More recently, the Kit ligand, termed stem cell factor (SCF), has been identified, cloned, and shown to be the product of the steel (Sl) locus in the m o u~e . '~-*~ It is clear from classical studies of W and SI mutant mice and from a variety of more recent in vitro and in vivo studies that the SCF/Kit system plays roles in gametogenesis, melanogenesis, and hematopoiesis during embryogenesis and postnatally as For example, ckif is expressed by early hematopoietic progenitor cells in fetal liver and in adult bone marrow (BM) and peripheral blood (PB),24-2h and in vitro, SCF has marked synergistic effects, along with later-acting factors such as erythropoietin or granulocyte CSF (G-CSF), in promoting colony formation by hematopoietic progenitor cells.'4~1s~19~20~27~28 In addition to expression in BM, PB, spermatogonia, oocytes, and melanocytes, c-kit is expressed postnatally in several other human tissues and cells, including brain astrocytes and glial cells, renal tubules, parotid acinar cells, thyrocytes, and breast epithelium.29.'" Stimulation with SCF induces dimerization of The second and third of the five IgG-like domains in the extracellular portion of the human Kit molecule have importance for SCF binding.34, 35 
On dimerization Kit undergoes tyrosine a u t o p h o~p h o r y l a t i o n ,~~~~~~~~~~~
and a number of mediators have been implicated in the subsequent intracellular signaling in different systems, including PI-3'-kinase, PLC-./, p21"', GAP, Raf-l, MAP kinases, p95'"', and protein kinase Naturally occurring soluble extracellular domains have been shown for a number of receptors and/or predicted on the basis of alternative splicings of receptor -As, as recently reviewed.44 For the split kinase receptor family, soluble extracellular domain has been described for PDGF (Y receptor; it is proteolytically released into the conditioned medium of the human osteosarcoma cell line MG-63 and is also detected in normal human blood plasma and serum. 45 The For personal use only. on October 22, 2017. by guest www.bloodjournal.org From domain is also present in serum, in substantial molar excess over SCF, and we describe its partial purification, and biochemical and functional properties.
MATERIALS AND METHODS
Enzyme-linked immunosorbent assay (ELISA) for soluble Kit. A sandwich type ELISA was developed, much like that developed previously for soluble SCF." The capturing antibody was an affinitypurified anti-Kit polyclonal antibody and the signal-generating antibody was purified SR-1, a neutralizing anti-Kit monoclonal antibody (MoAb)." The polyclonal antibody was produced in New Zealand White rabbits by immunization with pure Chinese hamster ovary (CHO) cell-derived recombinant human soluble Kit. The Kit-specific antibodies from the obtained antisera were isolated by binding to and subsequent elution from Actigel-ALD, which had C H 0 cellderived human soluble Kit covalently attached to it, following the manufacturer's instructions (Sterogene Bioseparations, Inc. Arcadia, CA). The signal-generating SR-1 MoAb was purified from mouse ascites fluid by using Protein G Sepharose resin (Pharmacia LKB, Piscataway, NJ) and was then covalently coupled to horseradish peroxidase (HRPO). SR-1 MoAb was first derivatized with 2-iminothiolane HCI (Fluka Chemical Corp, Ronkonkoma, NY)." Separately, HRPO was derivatized with N-succinimidyl 6-maleimidocaproate (Fl~ka).'~ The two activated proteins were combined to produce the covalently linked conjugate SR-1:HRPO. The conjugate was isolated by using a Superose 6 gel filtration column (Pharmacia). Immulon 4 Removawell strips (Dynatech Laboratories, Inc, Chantilly, VA) were coated with the affinity-purified rabbit anti-Kit antibody. One hundred microliters of TEN buffer (50 mmol/L Tris, 10 mmol/L EDTA, 150 mmol/L NaCI, pH 7.4 with 0.02% Thimerosal [Sigma Chemical CO, St Louis, MO]) containing 2.5 pg/mL of the antibody was placed in each well of the plates. The plates were then incubated for 24 hours at room temperature in a sealed humidity chamber. Two hundred microliters of blocking solution consisting of 1 % bovine serum albumin, 5 % sucrose in TEN buffer was added to each well, and the plates were incubated for an additional 24 hours at room temperature in the sealed humidity chamber. The coatingblocking solution mixture was removed from the wells that were then allowed to air dry for 24 hours and stored in sealed plastic bags at 4°C until use. To perform the ELISA for Kit, 100 pL of sample was added to the appropriate wells and incubation was performed for 2 hours at room temperature. The solution from each well was then removed followed by washing twice with 0.01% Tween 20 in TEN buffer. One hundred microliters of the SR-1:HRPO conjugate (0.25 pg/mL in TEN buffer containing 10% fetal bovine serum [FBS] ) was added. After 1 hour the solution was removed and the wells were washed four times with 0.01% Tween 20 in TEN buffer. The plates were incubated for 10 minutes at room temperature with 100 pL TMB Microwell Peroxidase substrate solution (Kirkegaard and Perry Laboratories, Inc, Gaithersburg, MD) and the HRPO reaction was then stopped by adding 100 pL of 0.5 N H2S04 to each well. The absorbances at 450 nm were read using a Molecular Devices Vmax Kinetic Microplate Reader (Molecular Devices Corp, Menlo Park, CA) with the SOFTmax (Molecular Devices) operating system controlled by a Macintosh SE computer (Apple Computer, Cupertino, CA). Pure CH0 cell-derived recomhinant human soluble Kit diluted into TEN buffer containing 2% FBS was used to generate standard curves. The concentration of pure recombinant soluble Kit stock solution was determined spectrophotometrically, using E&'$ of 1.18 L/g.cm calculated from the composition of aromatic amino acids and disulfide bondss4 Thus, concentration values represent polypeptide only; contribution from carbohydrate is not included. Standard curves were fairly linear from 0.5 to 10 ng/mL; however, a quadratic curve-fit gave a better correlation coefficient and was therefore used. The coefficient of variance for the indicated range of the assay was 7%.
Anti-Kit immunoafinity chromatography. SR-1 MoAb, purified using Affigel Protein A (BioRad Laboratories, Richmond, CA) was used for coupling to swelled CNBr-activated Sepharose 4B resin (Pharmacia) with blocking and washing, according to the manufacturer's instructions. Sixty-four milligrams of SR-I MoAb was coupled to 40 mL of resin, which was packed into a column (3.2 X 5.0 cm) and equilibrated with phosphate-buffered saline (PBS) containing additional NaCl of 350 mmoVL. Pooled human serum (12,860 mL; Biocell Laboratories, Inc, Rancho Dominguez, CA) was passed over the anti-Kit column at 180 mL/h at 4°C. The column was washed with 4,100 mL of equilibration buffer and eluted with 100 mmol/L acetic acid, 300 mmom NaCl, pH 2.67. Of the eluate, 110 mL was pooled and neutralized. (The pooled serum applied to the anti-Kit column had previously been clarified by filtration, treated with protease inhibitors, and passed over an anti-SCF immunoaffinity column in previously reportedso work, and was thus depleted of SCF.)
Glycosidase treatments followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. The serum-derived eluate from the anti-Kit immunoaffinity step (63.6 pL aliquots), and CH0 cell-derived human soluble Kit were subjected to glycosidase treatments at 37°C for 15. 
/&). SDS-PAGE was performed
with separating gels of 10% (wt/vol) acrylamide and stacking gels of 5% (wthol) acrylamide. Immunoblotting was performed according to Bumette" and immunocomplexes were visualized with a Vectastain ABC Kit (Vector Laboratories, Inc, Burlingame, CA).
Ligand afinity chromatography. For ligand affinity chromatography, 2 mg of Escherichia coli-derived recombinant human rose 4B resin (Pharmacia) with subsequent blocking and washing, according to the manufacturer's instructions. A column (1 . O X 1.27 cm) equilibrated with 20 mmoK Tris-HC1, 150 mmol/L NaCl, pH 7.5 was prepared. A portion (IO mL) of the eluate from anti-Kit immunoaffinity chromatography was dialyzed against the equilibration buffer and applied to the column at 10 mL/h. After washing the column with 11.5 mL of column equilibration buffer, stepwise elution was performed with increasing levels of urea in the column equilibration buffer: 25 mmoVL, 50 mmoVL, 100 mmol/L, 250 mmol/L, 500 mmol/L, 1 morn, 2 mol& 3 mol/L, and 4 mol/L of urea. A pool of 37.3 mL was made from the 1 through 4 m o m urea eluates. N-terminal amino acid sequence analysis. Sequence analysis was performed with an automated amino acid sequencer, Model 477A (Applied Biosystems, Inc, Foster City, CA) equipped with an on-line phenylthiohydantoin amino acid analyzer and a Model 610A data collection ~ystem.~' SDS-PAGE followed by electroblotting onto polyvinylidene difluoride (PVDF) membrane (Problott; Applied Biosystems) and Coomassie blue staining were performed according to the manufacturer's instructions. PVDF membrane pieces containing the blotted soluble Kit band were excised and subjected to sequencing. N-terminal sequence analysis was performed for five cycles (with no sequence detected). The PVDF membrane was removed from the sequencer and treated overnight at ambient temperature in a solution of 10% (wt/vol) CNBr in 70% (voVvol) formic acid. At the end of the digest, the PVDF membrane was transferred SCFI-16556 was coupled to 1 mL of swelled CNBr-activated Sepha- to a microfuge tube and dried under nitrogen. N-terminal sequence analysis was then performed for 20 cycles.
Other methods. SDS-PAGE was performed according to LaemmL5* Silver staining of gels was done according to M~rrissey.~' Competition binding of ['''IISCF in a membrane-bound receptor binding assay was performed as described by Smith and Zsebo.'" C H 0 cell-derived recombinant human soluble Kit was produced and purified as described.""" Based on the expressed sequence and expected processing of the signal sequence, the polypeptide backbone of this material has amino acids 24 through 520 of the sequence described by Yarden et aI2 (amino acids I through 23 correspond to the signal sequence) and has a molecular weight of 55,826 calculated from amino acid composition. Note that this recombinant material includes the four amino acids (510 through 513) that are unique to the Kit A isoform discussed above.
RESULTS AND DISCUSSION
The concentration of soluble Kit in normal human serum was measured using the ELISA that we developed. The distribution of soluble Kit levels in serum from 112 normal human blood donors is shown in Fig 1. The mean value was 324 ng/mL with an SD of 105 ng/mL. Values ranged from 163 ng/mL to 788 ng/mL. For a subgroup of 78 of the 112 blood donors the soluble Kit levels were analyzed with respect to the sex of the donors as shown in Table  1 , part A. The distribution of soluble Kit levels was normal both in the group of 33 females and in the group of 45 males. The data were analyzed according to the analysis of variance (ANOVA) method and no statistically significant difference in soluble Kit level existed between the two groups ( P = .73). with the mean being 37 years. The ANOVA method showed a statistical significance for the differences in soluble Kit levels as a function of the four age groups shown in Table  I , part B ( P = .01S). Therefore, we applied multiple comparison tests to indicate which of the age groups differed significantly from the others. A two-tailed Bonferroni t-test showed that statistical significance applied only to the difference in soluble Kit levels between those donors less than 30 years of age and those older than SO years.
Because SCF or other binding proteins could potentially influence the Kit ELISA results, and because soluble SCF is present in normal human serum in appreciable amounts," we tested for effects of soluble human SCF in the Kit ELISA. We included C H 0 cell-derived recombinant human or E coli-derived recombinant human soluble at concentrations as high as 4 pg/mL and 2 pg/mL, respectively, in the assay. Neither affected the quantitation of human serum-derived soluble Kit or C H 0 cell-derived recombinant human soluble Kit (data not shown).
To purify and further characterize the human serum-derived soluble Kit we used anti-Kit immunoaffinity chromatography. Table 2 shows that a substantial purification of about 55,000-fold was achieved with a yield of 76%. The final purity was approximately 20% such that it became possible to visualize the soluble Kit by SDS-PAGE followed by immunoblotting with polyclonal antibodies against C H 0 cell-derived recombinant human soluble Kit (Fig 2, lane 8) . The major visualized band migrates with an apparent molecular weight of about 98,000 daltons, similar to the pure C H 0 cell-derived recombinant soluble Kit in lane 1. No bands were seen in a control immunoblot where we used preim-SCF1-16547 sc~Ibl6S S6 (Fig 2, lane 7) , representing the 497 amino acids (amino acids 24 through S20 by the numbering of Yarden et al') of the Kit N-terminal extracellular domain. From the migration position of the major band in lane 14 of Fig 2, it appears that the polypeptide backbone of the human serum-derived soluble Kit is very similar in length to that of the C H 0 cell-derived recombinant soluble Kit, ie, it probably terminates near amino acid S20 as well, just before the transmembrane domain of the intact membrane-bound receptor. The 42,000-dalton reduction in mobility (from about 98,000 dalton to about 56,000 dalton) of both recombinant (Fig 2, lanes 2 and 7) and serum-derived (Fig 2, lanes 9 and 14) soluble Kit upon complete deglycosylation is in agreement with the 39.000-dalton difference in mobility previously seen between the 14S.000-dalton glycosylated and 106,000-dalton unglycosylated mature fulllength Kit," reflecting the fact that all glycosylation is on the extracellular domain.
The purity after imrnunoaffinity chromatography was also sufficient that the soluble Kit could be visualized directly by silver-staining after SDS-PAGE (Fig 3) . Note that the amount of immunoaffinity column eluate loaded in lane S of Fig 3 is derived from S mL of original serum, so in this sense it represents a 20,000-fold greater load than that of the serum (0.25 pL) in lane 2. The band at about 98,000 daltons in lane S almost certainly represents soluble Kit. Its migration position matches that of the major band visualized by immunoblotting (Fig 2, lane 8) and that of C H 0 cellderived recombinant soluble Kit visualized by silver staining (Fig 3, lane 6 ). In addition, from the ELISA value of Table  2, The fact that the staining of the -98,000-dalton bands in lanes S and 6 is also similar in intensity is consistent with the -98.000-dalton band in lane S being soluble Kit, and again corroborates the quantitation determined by ELISA. The soluble Kit band at about 98,000 daltons in lane S is one of five prominent bands that stain about equally. This observation supports the data from Table 2 , which indicate that following immunoaffinity chromatography the soluble Kit is about 20% pure.
We used N-terminal amino acid sequencing to further verify the identity of the soluble Kit. As described in Materials and Methods. a portion ( I O mL) of the immunoaffinity purified material was subjected to ligand affinity chromatography (additional purification of about threefold was obtained) followed by SDS-PAGE with electroblotting. No amino acid signals were detected in five cycles of N-terminal sequencing of the electroblotted band, indicating that the Nterminus is blocked to Edman degradation. After treating the electroblotted band with CNBr (which cleaves after methionine residues), N-terminal sequencing showed multiple amino acids at each cycle (Table 3) . At each cycle, the amino acids corresponded to those expected for the five cyanogen bromide peptides predicted from the Kit extracellular domain (excepting that derived from the blocked N-terminal segment). These results strongly support the conclusion that the electroblotted band represents Kit extracellular domain. It is noteworthy that, as for the electroblotted band, direct Nterminal sequencing of CH0 cell-derived recombinant soluble Kit gives no signals, ie, the N-terminus of the recombinant material is blocked to Edman degradation as well. The results suggest that at least some of the soluble Kit in serum is functionally capable of binding SCF. The apparently low specific activity of binding compared with that of the recombinant soluble Kit could reflect intrinsic differences in structure of the polypeptides or attached carbohydrate. Alternatively, there could be protein or factors specifically bound to the serum-derived soluble Kit which inhibit SCF binding. More trivial explanations would include disruption of structure and activity (but not ELISA reactivity) by exposure to the low pH conditions used for immunoaffinity column elution in the purification, or components in the partially pure soluble Kit that nonspecifically interfere in the binding assay.
As mentioned, SCF, the ligand for Kit, itself exists in both membrane-bound and soluble forms,J"J" and soluble SCF is 
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After treating PVDF membrane with CNBr, sequencing, and comparing sequencing data to expected sequences from the extracellular portion of Kit receptor, the assignments of all five of the postmethionyl sequences could be made. Positions designated as X are predicted to be cysteine.
For present at about 3.3 ng/mL in human serum (ie, about 177 pmol/L in terms of SCF monomer; note that SCF is a noncovalently held dimer in solution). Cases such as this, where both the ligand SCF and the receptor Kit exist in membranebound and soluble forms, deviate from the classical picture of membrane-bound receptor being activated by soluble ligand, as recently discussed.a Two general mechanisms exist whereby soluble receptor forms can be generated: proteolytic release of the extracellular domain or alternative splicing leading to mRNA encoding only the extracellular domain.a The former mechanism seems most likely for soluble Kit, because mRNA splice variants corresponding to the extracellular domain have not been reported. Presumably the release would reflect regulatory mechanisms by which cell-surface Kit is downregulated in some or all of the various cell types that express it. As mentioned, alternative splicing in exon 9 determines the presence or absence of four amino acids in the extracellular domain just before the transmembrane domain.'," It is possible that these alternative forms could differ in a proteolytic cleavage recognition site and therefore differ in their tendency to undergo proteolytic processing with release of soluble extracellular domain. If so, the situation would be similar to that for SCF, where alternative splicing determines the presence or absence of exon 6, which encodes an extracellular proteolytic cleavage ~i t e .~' .~~
In view of the relatedness between c-kit and c-fms, the gene that encodes the receptor for M-CSF, it is of interest that protein kinase C has been shown to activate a specific proteolytic cleavage of the receptor for M-CSF at a site just before its transmembrane domain.'* It has been shown that soluble Kit is present in the conditioned medium of certain cell lines""; these can be studied to further understand the mechanism and regulation of soluble Kit release.
The levels of soluble Kit in human serum (324 ng/mL = 5.8 nmol/L) are quite high and represent a surprisingly large excess over the soluble SCF present (33-fold excess on a molar basis). High-affinity (kd values of 16 to 310 pmoVL) full-length Kit receptors have been reported for human cell line~,6'.~ marrow blast cells from acute myeloid leukemia patients," and for marrow mononuclear cells from DiamondBlackfan anemia patients and normal patients.% For some of the cell lines:' and for many of the acute myeloid leukemia blast cases,6s lower affinity receptors (kd values of 1.8 to 65 nmol/L) were reported as well. kd values in the vicinity of 1 nmol/L have been reported for a recombinant human soluble Kit.'*"','' Given the values of 3.3 ng/mL (177 pmol/ L in terms of monomer) for SCF and 324 ng/mL (5.8 nmoV L) for soluble Kit in serum, one can speculate about the extent to which SCF/soluble Kit complexes might exist. Assuming a probably over-simplified situation of one SCF monomer interacting with one soluble Kit monomer, and further assuming a kd of 1 nmol/L, one can calculate from equilibrium kinetics that the concentration of complex would be about 150 nmol/L, ie, about 85% of the total SCF would be present in the form of complex. Because of the large excess of soluble Kit, the 150 nmol/L concentration of complex would include only about 2.5% of the total soluble Kit.
It remains to be determined what role soluble Kit may play in modulating SCF function in vivo. Soluble Kit could act as an SCF antagonist by blocking (competing for) SCF binding to membrane-bound receptor, or by undergoing SCF-mediated association with membrane-bound Kit, thereby blocking normal receptor dimerization, autophosphorylation, and signal transduction. The soluble Kit could also serve to chaperone SCF in the circulation and prevent its degradation. Because SCF can exist in membrane-bound form, and because it appears that the cytoplasmic domain of membrane-bound SCF can have a functional role," it is possible that soluble Kit could stimulate SCF-mediated signal transduction in cells that bear the membrane-bound SCF.
The finding that soluble Kit with functional SCF binding properties is present in serum is relevant to the development of therapeutic uses for SCF that is in progress,68.6' ie, it is of interest to understand to what extent soluble Kit might modulate the action of exogenously administered, as well as endogenous, SCF. It will also be of interest to determine by the ELBA whether soluble Kit levels change in any disease states or clinical settings. Knowledge of such changes could be useful diagnostically.
